

Confide Pharmaceuticals Private Limited

Balance Sheet as at 31st March, 2021

(Amount in ₹)

(Amount in ₹)

	Particulars	Note No.	As at 31st March 2021	As at 31st March 2020
I	EQUITY & LIABILITIES			
(1)	Shareholders' Funds			
	Share Capital	1	100,000	100,000
	Reserves and Surplus	2	(650,484)	149,512
	Money received against share warrants	-		-
(2)	Share application money pending allotment			-
(3)	Non-Current Liabilities			
	Long-term Borrowings	-		-
	Deferred Tax Liabilities (Net)	11	1,028	3,765
	Other Long-term Liabilities	-		-
	Long-term provisions	-		-
(4)	Current Liabilities			
	Short-term borrowings	3		
	Trade payables	4	1,042,980	954,500
	Other current liabilities	5		
	Short-term provisions	6	525,000	1,260,142
	TOTAL		1,018,524	2,467,919
II	ASSETS			
(1)	Non-Current Assets			
	Fixed Assets	-		-
	Tangible Assets	7	48,108	78,141
	Other Non Current Assets	-		-
	Deferred Tax Asset (Net)	11		-
	Unamortised Expenses	8		-
(2)	Current Assets			
	Cash and cash equivalents	9	147,091	1,034,302
	Trade Receivables	10	523,770	1,136,476
	Other current assets	13	100,000	100,000
	Short Term Loan & Advances	14	199,555	119,000
	TOTAL		1,018,524	2,467,919
	See accompanying notes forming part of the financial statements			

In terms of our report attached
For Amrutesh Durga & Co.,
Chartered Accountants
FRN: 013370S

For and on behalf of the Board of Directors

(CA. Amrutesh Durga)
Partner
Membership No:219424
UDIN: 21219424AAAAER7800

Ajay Mishra
Director
(DIN-07799251)

Kalpana Tripathi
Director
(DIN-07799501)

Place: Bangalore
Date: 01/11/2021

Confide Pharmaceuticals Private Limited

Profit and Loss Statement for the year ended 31st March, 2021

(Amount in ₹)

	Particulars	Note No.	For the year ended 31 March, 2021	For the year ended 31 March, 2020
1	Revenue from operations	-	709,835	3,711,098
2	Other income	-	-	460
3	Total revenue (1+2)		709,835	3,711,558
4	Expenses			
	Purchase		546,889	479,192
	Employee Benefits Expense	-	660,000	1,137,124
	Depreciation and amortization expense	7	32,667	26,097
	Other Expenses	12	275,068	1,719,075
	Total expenses		1,514,624	3,361,488
5	Profit / (Loss) before tax (3 - 4)		(804,789)	350,070
6	Tax expense:			
	Current tax expense for current year	-	-	91,018
	(Less): MAT credit (where applicable)	-	-	-
	Current tax expense relating to prior years	-	-	-
	Net current tax expense	-	-	91,018
	Deferred tax	II	(4,793)	1,716
7	Profit / (Loss)		(799,996)	257,336
	Earning Per Equity Share Basic & Diluted		(80)	26
	Weighted Average No Of Equity share		10,000	10,000
	Significant Accounting Policies See Accompanying notes to the Financial Statement			

In terms of our report attached
For Amrutesh Durga & Co.,
Chartered Accountants
FRN: 013370S

For and on behalf of the Board of Directors

(CA. Amrutesh Durga)
Partner
Membership No: 219424
UDIN: 21219424AAAAER7800

Ajay Mishra
Director
(DIN-07799251)

Kalpana Tripathi
Director
(DIN-07799501)

Place: Bangalore
Date: 01/11/2021

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note 1: Share Capital

Particulars	(Amount in ₹) As at 31st March 2021	(Amount in ₹) As at 31st March 2020
	AUTHORISED 1,00,000 Equity Shares of Re.10/- each	1,000,000
	1,000,000	1,000,000
ISSUED, SUBSCRIBED AND PAID-UP 10,000 Equity Shares of Re.10/- each, fully paid	100,000	100,000
Additions during the year	-	-
	100,000	100,000

Details of Shareholder holding more than 5% shares:

Name of Share holder	As at 31st March 2021	As at 31st March 2020
	No of Shares	No of Shares
Ajay Kumar Mishra	4,000	4,000
Kalpana Tripathi	6,000	6,000
	10,000	10,000

Reconciliation of number of shares:

Particulars	As at 31st March 2021	As at 31st March 2020
	No of Shares	No of Shares
Equity Shares -Opening Balance	10,000	10,000
Add: Shares issued during the year	-	-
Equity Shares- Closing Balance	10,000	10,000

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note 2 : Reserves and Surplus

(Amount in ₹)

Particulars	As at 31st March 2021	As at 31st March 2020
General Reserves		
Opening Balance	149,512	-107,824
Add: Transferred from Surplus in Profit and Loss	-799,996	257,336
Closing Balance	-650,484	149,512
Surplus in the Profit and Loss		
Opening Balance		
Add: Net Profit/ Loss for the year	-799,996	257,336
Amount available for appropriation	-799,996	257,336
Less : Appropriation		
Transferred to General Reserve	-799,996	257,336
Net Surplus	-	-
Total Reserve and Surplus	-650,484	149,512

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note 3: Short-term borrowings		
	(Amount in ₹)	(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Unsecured Loan From Directors	-	-
TOTAL	-	-
Note 4: Trade Payables		
	(Amount in ₹)	(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Sundry Creditors	1,042,980	954,500
TOTAL	1,042,980	954,500
Note 6 : Short Term Provisions		
	(Amount in ₹)	(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Provision:		
Audit Fee Payable	45,000	32,000
Income Tax Payable	-	91,018
Remuneration to Director-Ajay Mishra	480,000	480,000
Remuneration to Employees	-	657,124
GST Tax Payable	-	-
TOTAL	525,000	1,260,142

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note : 7 FIXED ASSETS

As per Companies Act 1956

(Separate sheet is there)

3/31/2021

Particulars	Date of Purchase	C o s t				D e p r e c i a t i o n				Net Book Value as at 31.3.2021
		Cost of Asset 1.4.2020	Res@5% Residual Value	Depreicable value	Life of Asset	Depreciation Year 1.4.2020	Dep on No of Days	No of usage	For the Year Dep 31.3.2021	
a) Tangible Assets										
Furniture and Fixtures	4/1/2016	32,148	1,607.40	30,540.60	10	14,600	40	1,825.00	18,250	13,898
Office Equipment	6/1/2016	23,871	1,193.55	22,677.45	3	4,197	11	1,764.00	5,292	18,579
Computers	4/1/2016	24,756	1,237.80	23,518.20	5	7,300	20	1,825.00	9,125	15,631
Total		80,775	4,039	76,736	18	26,097	71	5,414	32,667	48,108

As per Income Tax Act

Particulars	Depreciation rate	W.D.V as on 1/04/2020	Addition During the Year		Deletion During the Year	31.3.2020	Depreciation for the Year	W.D.V as on 31/03/2021
			More than 180 Days	Less than 180 Days				
Furniture and Fixtures	10%	47,746	-	-	47,746	-	4,775	42,971
Office Equipment	15%	21,359	-	-	21,359	-	3,204	18,155
Computers	40%	15,635	-	-	15,635	-	6,254	9,381
Total Intangibles		84,740	-	-	84,740	-	14,232	70,508

Note 6 - Depreciation and amortisation relating to continuing operations:

Particulars	For the year ended
Depreciation and amortisation for the year on tangible assets as per Note 6 A	32,667
Depreciation and amortisation for the year on intangible assets as per Note 6 B	-
Less: Utilised from revaluation reserve	-
Depreciation and amortisation relating to discontinuing operations	-
Depreciation and amortisation relating to continuing operations	-

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note 9 : Cash and cash equivalents	(Amount in ₹)	(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Cash on hand	5,865	5,865
Balances with banks In current accounts	141,226	1,028,467
TOTAL	147,091	1,034,332
Note : 12 Other Expenses		(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Audit Fee	45,000	35,000
Business Promotion expenses	100,300	1,490,020
Bank Charges	1,593	708
Courier Charges		5,899
Donation	-	
Design & Packing Materials		24,600
Miscellaneous Expenses	6,100	13,568
Office Expenses	44,075	1,400
Office Rent	78,000	72,000
Registration Expenses	-	-
Testing Charges		3,526
Transportation Expenses		19,954
Website Design Charges	-	-
Professional Charges		52,400
TOTAL	275,068	1,719,075
Note : 10 Trade Receivables		
Particulars	As at 31st March 2021	As at 31st March 2020
Sundry debtors	523,770	1,136,476
TOTAL	523,770	1,136,476
Note : 8 Other Non-Current Assets		(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Preliminary Expenses	-	
Less: Preliminary Expenses W/O for the year	-	-
TOTAL	-	-
Note : 13 Other Current Assets		(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Share Application Money Received	100,000	100,000
TOTAL	100,000	100,000
Note : 14 Short Term Loan & Advances		(Amount in ₹)
Particulars	As at 31st March 2021	As at 31st March 2020
Rental Deposit-Office Premises	40,000	40,000
Clinder, Freight & Security Deposits	35,000	35,000
TM, R Producers	44,000	44,000
Advance Payment to Suppliers	80,555	-
TOTAL	199,555	119,000

Confide Pharmaceuticals Private Limited

Notes forming part of the financial statements

Note 11 : Deferred Tax Liability

Particulars	As per Books	As per Income Tax	Timing Difference	Deferred Tax Liability
Opening Balance				3,765
Depreciation	32,667	14,232	18,435	-4,792.98
Preliminary Expenses W/O	-	-	-	-
Total	32,667	14,232	18,435	(1,028)

Creditors

Dr.	Rs.	Cr.	Rs.
		OB	954,500
To Bank	458,409	Purchases	546,889
To Balance C/d	1,042,980		
	1,501,389		1,501,389

Debtors

Dr.	Rs.	Cr.	Rs.
OB	1,136,476	Receipts	1418493.05
Sales	709,835	To Balance C/d	427,818
	1,846,311		1,846,311

Advance to Suppliers:

Pace Biot	25000
Clinffid	15000
Fen	20000
Hepamet	20555
Total	80555